Schedule 13D ownership disclosure

ARS Pharmaceuticals Inc

Common Stock, par value $0.0001 per share · CUSIP: 82835W108

Event date: 2025-07-30

Reporting persons may disclose overlapping interests. Their amounts are shown individually and are not added into a filing total.

Filing-level shares
Unavailable
Percent of class
Unavailable
  • Deerfield Mgmt III, L.P.Reported CIK 0001610540

    Shares: 3,805,108.00 · Class: 3.87%

  • Deerfield Private Design Fund III, L.P.Reported CIK 0001603333

    Shares: 3,805,108.00 · Class: 3.87%

  • Deerfield Mgmt IV, L.P.Reported CIK 0001713467

    Shares: 3,805,109.00 · Class: 3.87%

  • Deerfield Private Design Fund IV, L.P.Reported CIK 0001680307

    Shares: 3,805,109.00 · Class: 3.87%

  • Deerfield Management Company, L.P.Reported CIK 0001009258

    Shares: 7,610,217.00 · Class: 7.75%

  • James E. FlynnReported CIK 0001352546

    Shares: 7,610,217.00 · Class: 7.75%

Amounts are as disclosed in this filing. Schedule type alone does not establish investment intent.

Source: SEC EDGAR filing

Filing metadata

Accession number
0001193805-25-001146
Form type
SCHEDULE 13D/A
Filer
ARS Pharmaceuticals, Inc.
CIK
CIK 1671858
Filed
Aug 01, 2025
Reporting period
Jul 30, 2025
Description
Schedule 13D beneficial ownership

Explore SEC Filings Hub